Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad pipeline across kidney disease, neuropathic pain, type 1 diabetes and other serious conditions. The VRTX news feed on Stock Titan brings together company press releases and other coverage that highlight how its commercial portfolio and research programs are evolving over time.
News about Vertex often focuses on clinical data readouts, regulatory milestones and commercial updates. Recent announcements have covered progress in cystic fibrosis, including data on ALYFTREK and other CFTR modulators presented at scientific conferences, and updates on next-generation CFTR correctors and CFTR mRNA therapies. Vertex also regularly reports on CASGEVY, its CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, including longer-term outcomes data and plans for regulatory submissions in additional age groups.
Investors and followers of VRTX news can also expect updates on JOURNAVX, the company’s oral non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in adults, including information on prescription trends, payer coverage and hospital formulary adoption. In kidney diseases, Vertex issues news on povetacicept and inaxaplin, including Phase 1/2 and Phase 3 trial data in IgA nephropathy, primary membranous nephropathy and APOL1-mediated kidney disease, as well as regulatory designations such as Breakthrough Therapy and Fast Track.
Additional news items may include financial results, participation in major healthcare investor conferences, and updates on programs in type 1 diabetes, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. For anyone tracking VRTX stock, this news page offers a centralized view of how Vertex’s marketed products and pipeline advance through clinical development, regulatory review and commercialization.
Vertex (NASDAQ: VRTX) announced U.S. FDA label expansions for ALYFTREK and TRIKAFTA, extending ALYFTREK to people with CF ages 6+ and TRIKAFTA to ages 2+ when variants are responsive or produce CFTR protein. The expansions cite responses for 564 variants (ALYFTREK) and 521 variants (TRIKAFTA), adding ~800 eligible U.S. patients and bringing coverage to ~95% of people with CF in the U.S.
The labels include prominent safety guidance on drug-induced liver injury, hypersensitivity, intracranial hypertension, neuropsychiatric events, and recommended monitoring schedules.
Vertex (Nasdaq: VRTX) reported positive Week 36 interim Phase 3 RAINIER results for povetacicept in adults with IgA nephropathy (IgAN). The trial met its primary and two alpha-controlled secondary endpoints with statistically significant reductions: UPCR -49.8% vs placebo (P<0.0001), Gd-IgA1 -79.3% vs placebo (P<0.0001), and hematuria resolution +61.7% vs placebo (P<0.0001).
Povetacicept was generally safe and well tolerated, with no deaths or opportunistic infections reported. Vertex will complete its BLA submission by end of March and is pursuing potential FDA accelerated approval with a priority review voucher.
Vertex (Nasdaq: VRTX) will participate in two investor conferences in March 2026. Management will join fireside chats at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 11:30 a.m. ET.
Speakers include Charlie Wagner and Duncan McKechnie at Leerink, and Susie Lisa and Miroslava Minkova at Barclays.
Vertex (Nasdaq: VRTX) announced Phase 4 data showing JOURNAVX (suzetrigine) enabled opioid-free recovery in plastic surgical patients. In a 99-patient, open-label study, 90.9% were opioid free through treatment (up to 14 days) and 90.7% rated effectiveness as excellent, very good, or good (95% CI: 83.1%, 95.7%). No serious adverse events related to JOURNAVX were reported. Data accepted for oral presentation at AAPM PainConnect 2026 on March 6, 2026.
Vertex (NASDAQ: VRTX) management will participate in TD Cowen’s 46th Annual Health Care Conference on March 3, 2026. CEO Reshma Kewalramani will appear in a fireside chat at 9:10 a.m. ET. A live webcast and archived replay will be available in the Investors > News and Events section.
Vertex (NASDAQ: VRTX) reported strong commercial results and guidance on February 12, 2026. Full year 2025 total revenue was $12.0 billion (+9% year-over-year) and Q4 2025 revenue was $3.19 billion (+10% year-over-year). GAAP net income was $4.0 billion and non-GAAP net income was $4.7 billion. Cash and marketable securities totaled $12.3 billion at year-end.
Vertex provided 2026 guidance of $12.95–$13.1 billion total revenue and at least $0.5 billion from non-CF products, with combined GAAP R&D, AIPR&D and SG&A expense guidance of $6.3–$6.45 billion.
WuXi Biologics and Vertex (VRTX) signed a license and research service agreement dated Feb 2, 2026, covering an innovative trispecific T‑cell Engager (TCE) for B‑cell mediated autoimmune diseases.
Vertex receives exclusive global development and commercialization rights at the preclinical stage; WuXi Biologics will receive an upfront payment, potential development/regulatory/sales milestones and royalties, and will provide contract R&D services on next‑generation TCEs.
Satellos (GBIO) appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs on January 29, 2026.
Ms. Paone joins from Generation Bio where she served as Chief Operating Officer and previously led regulatory strategy at Vertex, including work on Kalydeco and Orkambi. Satellos says her hire supports advancement of two SAT-3247 clinical studies in adult and pediatric DMD populations.
Vertex (NASDAQ: VRTX) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. The company will host a conference call and webcast at 4:30 p.m. ET.
Dial-in numbers: (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The live webcast will be available in the Investors section of Vertex's website and an archived webcast will be posted. Participants are recommended to register at least 15 minutes before the webcast to ensure timely connection.
Vertex (Nasdaq: VRTX) provided business and pipeline updates ahead of investor meetings and a webcast at the J.P. Morgan Healthcare Conference on January 12, 2026. Key commercial milestones in 2025 include >$100 million in CASGEVY revenue and >500,000 JOURNAVX prescriptions with access for ~200 million covered lives. Vertex reported multiple regulatory and clinical milestones: a rolling BLA for povetacicept with priority review voucher and Breakthrough designation, RAINIER full enrollment, planned pivotal submissions for CASGEVY pediatric use in H1 2026, and several mid/late‑stage studies delivering data or completing enrollment across CF, renal, pain, and other programs.